21:44 , Oct 10, 2018 |  BC Extra  |  Politics & Policy

China adds insurance coverage for 17 cancer therapies

China's National Medical Insurance Administration added 17 cancer drugs to the National Reimbursement Drug List (NRDL) for coverage by the country's medical insurance program. The prices will go into effect by the end of October...
20:34 , Aug 17, 2018 |  BC Extra  |  Politics & Policy

China unveils cancer drugs for medical insurance access negotiation

China's State Medical Insurance Administration announced 18 cancer drugs that will be included in 2018 medical insurance access negotiations. Companies with drugs on the list will now enter into negotiations to include the drugs on...
03:05 , Jun 30, 2018 |  BioCentury  |  Finance

Hidden in the rough

Judicious stock picking was especially important in the second quarter, as 57% of global biotech stocks saw their equity values decline. Volatility continued to roil global markets during the period and additional uncertainty looms with...
02:29 , May 18, 2018 |  BC Week In Review  |  Clinical News

CTTQ's tyrosine kinase inhibitor gets Chinese approval for NSCLC

The State Drug Administration (formerly CFDA) approved Focus V anlotinib from Chia Tai Tianqing Pharmaceutical Group Co. Ltd. (Nanjing, China) to treat advanced non-small cell lung cancer. CTTQ has Chinese rights to anlotinib from Advenchen...
21:18 , May 11, 2018 |  BC Extra  |  Company News

CTTQ's tyrosine kinase inhibitor gets Chinese approval for NSCLC

The State Drug Administration (formerly CFDA) approved Focus V anlotinib from Chia Tai Tianqing Pharmaceutical Group Co. Ltd. (Nanjing, China) to treat advanced non-small cell lung cancer. CTTQ has Chinese rights to anlotinib from Advenchen...
00:57 , Jul 21, 2017 |  BC Week In Review  |  Clinical News

Chia Tai Tianqing reports Phase III data for anlotinib in NSCLC

Chia Tai Tianqing Pharmaceutical Group Co. Ltd. (Nanjing, China) reported data from the Phase III ALTER0303 trial in 437 patients with stage IIIB/IV non-small cell lung cancer (NSCLC) who progressed after ≥2 lines of therapy...
19:51 , Mar 15, 2017 |  BC Week In Review  |  Clinical News

Apatinib: Ph III ANGEL started

LSK began the double-blind, placebo-controlled, international Phase III ANGEL trial to compare oral apatinib daily plus best supportive care (BSC) vs. BSC alone in about 459 patients who have failed ≥2 prior lines of standard...
07:00 , May 16, 2016 |  BC Week In Review  |  Company News

Clovis cancer news

Clovis will reduce staff and contractor positions by 35% by year end compared to the end of 2015 and will reprioritize resources from rociletinib to its next most-advanced candidate, rucaparib. Clovis stopped enrollment in all...
08:00 , Nov 10, 2014 |  BC Week In Review  |  Clinical News

Lucitanib: Phase II started

Clovis began an open-label, international Phase II trial to evaluate once-daily oral lucitanib, starting at 15 mg/day, in 28-day cycles in about 40 patients. The dose can be reduced in 2.5 mg/day increments to 5...
07:00 , Jul 21, 2014 |  BC Week In Review  |  Clinical News

Lucitanib: Additional Phase II data

Additional data from the Phase IIa extension of an open-label, dose-escalation Phase I trial showed that once-daily 10, 15 or 20 mg lucitanib led to 6 objective responses and 6 cases of stable disease in...